The phrase "acquire gain" is not commonly used in written English and may sound awkward.
It could be used in contexts discussing the process of obtaining benefits or profits, but it is not a standard expression.
Example: "The company aims to acquire gain through strategic investments in emerging markets."
Alternatives: "obtain profit" or "achieve benefits".
Son defined his tactics as "diplomatic warfare" in which both Softbank and the firm it sought to acquire gained something without having engaged in an all-or-nothing confrontation.
We further speculate that PIK3CA mutation in MCF7 cells could acquire gain-of-function (e.g., PI3K/AKT activation) during development of antiestrogen resistance, resulting in genomic instability and contributing to the resistant phenotypes.
That prostate cancer can spontaneously acquire gain-of-function mutations in AR (rather than acquiring mutations that simply preclude inhibitor binding) underscores the special challenge in pharmacologically overcoming this mechanism of resistance.
These results indicate that the p53R270H point mutation, apart from having a dominant-negative affect on the wild-type p53 allele, may also acquire gain-of-function, which facilitates acceleration of mammary tumour development.
The finding that Avr3c is a multi-copy RXLR effector that acquired gain of virulence mutations that spread through sequence exchanges provides a new example of the plasticity of the RXLR effector family.
This tumour acquired gain of 1q and loss of 16q, having shown a balanced profile at first surgery.
NSCLC is frequently associated with epidermal growth factor receptor (EGFR) over expression, gene amplification and acquired gain of function mutations.
However, the acquired gain in CFHR3, MDFIC, CSMD3, FOXP2, or RALYL and loss in SLC25A17, POLDIP3, SERHL, LOC400927, MGAT3, or TTLL1 drive poor patient outcomes.
In contrast to WT-p53, aberrant p53 proteins can lose their tumour suppressor functions and give rise to highly stabilised mutant proteins with an acquired gain of function participating in EMT and tumour progression (Oren and Rotter, 2010; Kogan-Sakin et al, 2011; Termen et al, 2013).
Mutant p53 acquires gain-of-function oncogenic activities that are dependent on its enhanced stability.
